(Q35769323)

10 August 2017

1 reference

title

HIV-related lipodystrophy and related factors (English)

1 reference

10 August 2017

Andrew M Tershakovec

1

1 reference

10 August 2017

Ian Frank

series ordinal

2

1 reference

10 August 2017

Daniel Rader

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

174

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

1-10

1 reference

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Management of dyslipidemia in patients with HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Clinical assessment of HIV-associated lipodystrophy syndrome: bioelectrical impedance analysis, anthropometry and clinical scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of Lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Lipodystrophy in patients naive to HIV protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Adverse effects of antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Lipodystrophy following antiretroviral therapy of primary HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Metabolic complications associated with antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Mitochondrial toxicity hypothesis for lipoatrophy: a refutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Complete reversibility of severe nucleoside-induced lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Plasma lipids in HIV-infected patients: a prospective study in 95 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Non-insulin-mediated glucose uptake in human immunodeficiency virus-infected men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Lipodystrophy in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Normal triglyceride levels in early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

High triglyceride levels as a predictor of mortality in AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

HIV nucleoside analogues: new adverse effects on mitochondria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

An argument for mitochondrial toxicity in highly active antiretroviral therapy-induced lipoatrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Toxicity of nucleoside-analogue reverse-transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Effects of antiretroviral drug combinations on the differentiation of adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Metabolic basis of HIV-lipodystrophy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900246-6

10.1016/S0021-9150(03)00246-6

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference